A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

Liaqat Ali; Gauri Saxena; Meleri Jones; Georgia R Leisegang; Luke Gammon; Sharmilee Gnanapavan; Gavin Giovannoni; Klaus Schmierer; David Baker; Angray S Kang

doi:10.2144/btn-2019-0122

BioTechniques (Apr 2020)

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

Liaqat Ali,
Gauri Saxena,
Meleri Jones,
Georgia R Leisegang,
Luke Gammon,
Sharmilee Gnanapavan,
Gavin Giovannoni,
Klaus Schmierer,
David Baker,
Angray S Kang

Affiliations

Liaqat Ali: 1Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK
Gauri Saxena: 1Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK
Meleri Jones: 1Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK
Georgia R Leisegang: 3Centre for Oral Immunobiology & Regenerative Medicine, Institute of Dentistry, Barts & the London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK
Luke Gammon: 1Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK
Sharmilee Gnanapavan: 4BartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK
Gavin Giovannoni: 4BartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK
Klaus Schmierer: 4BartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK
David Baker: 4BartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK
Angray S Kang: 3Centre for Oral Immunobiology & Regenerative Medicine, Institute of Dentistry, Barts & the London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK

DOI: https://doi.org/10.2144/btn-2019-0122
Journal volume & issue: Vol. 68, no. 4
pp. 185 – 190

Abstract

Read online

Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. Results: Alemtuzumab–Alexa Fluor 488 conjugate binding to the CHO-CD52 cell surface was inhibited by anti-alemtuzumab antibodies. Conclusion: In this proof-of-concept study, a CHO-CD52 cell line has been developed and used to detect the presence of anti-alemtuzumab neutralizing antibodies. This platform provides the basis of an assay for routine screening of serum for neutralizing antibodies from patients treated with alemtuzumab.

Published in BioTechniques

ISSN: 0736-6205 (Print); 1940-9818 (Online)
Publisher: Future Science Ltd
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.future-science.com/journal/BTN

About the journal

Abstract

Keywords